The latest from Cogstate, leaders in optimizing the measurement of cognition

Take a gamble on market stocks

March 1, 2013

Herald Sun Criterion columnist, Tim Boreham reported on the Myer family’s 19.3 per cent investment in CogState and the use of Cognigram in Canada, which is the first test used outside of clinical trials for Alzheimers disease.

Boreham states, “He (Brad O’ Connor) estimates the cognitive testing market globally is worth about $500m. Canada, in effect a pilot market, could be worth ‘millions of dollars’ in revenues with 150 GPs interested in using the test.”

Read the full article here.